SI2790699T1 - Farmacevtska zmes z izboljšano biološko razpoložljivostjo za hidrofobno spojino z visokim tališčem - Google Patents
Farmacevtska zmes z izboljšano biološko razpoložljivostjo za hidrofobno spojino z visokim tališčemInfo
- Publication number
- SI2790699T1 SI2790699T1 SI201230958A SI201230958A SI2790699T1 SI 2790699 T1 SI2790699 T1 SI 2790699T1 SI 201230958 A SI201230958 A SI 201230958A SI 201230958 A SI201230958 A SI 201230958A SI 2790699 T1 SI2790699 T1 SI 2790699T1
- Authority
- SI
- Slovenia
- Prior art keywords
- pharmaceutical composition
- high melting
- hydrophobic compound
- improved bioavailability
- melting hydrophobic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161569863P | 2011-12-13 | 2011-12-13 | |
| PCT/EP2012/074884 WO2013087546A1 (fr) | 2011-12-13 | 2012-12-10 | Composition pharmaceutique à biodisponibilité améliorée, destinée à un composé hydrophobe à point de fusion élevé |
| EP12801538.5A EP2790699B2 (fr) | 2011-12-13 | 2012-12-10 | Composition pharmaceutique à biodisponibilité améliorée, destinée à un composé hydrophobe à point de fusion élevé |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2790699T1 true SI2790699T1 (sl) | 2017-06-30 |
Family
ID=47358159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201230958A SI2790699T1 (sl) | 2011-12-13 | 2012-12-10 | Farmacevtska zmes z izboljšano biološko razpoložljivostjo za hidrofobno spojino z visokim tališčem |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20130172375A1 (fr) |
| EP (1) | EP2790699B2 (fr) |
| JP (1) | JP5936705B2 (fr) |
| KR (1) | KR101637793B1 (fr) |
| CN (1) | CN103998037B (fr) |
| BR (1) | BR112014010290B8 (fr) |
| CA (1) | CA2850706C (fr) |
| DK (1) | DK2790699T3 (fr) |
| ES (1) | ES2627531T5 (fr) |
| HU (1) | HUE034548T2 (fr) |
| MX (1) | MX348654B (fr) |
| PL (1) | PL2790699T5 (fr) |
| RU (1) | RU2014127142A (fr) |
| SI (1) | SI2790699T1 (fr) |
| WO (1) | WO2013087546A1 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008063888A2 (fr) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées |
| AU2010232670B2 (en) * | 2009-04-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof |
| PE20121327A1 (es) | 2009-11-06 | 2012-10-18 | Plexxikon Inc | Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello |
| PL2672967T3 (pl) | 2011-02-07 | 2019-04-30 | Plexxikon Inc | Związki i sposoby modulacji kinaz i wskazania ku temu |
| TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
| US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| KR20150038068A (ko) | 2012-08-17 | 2015-04-08 | 에프. 호프만-라 로슈 아게 | 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법 |
| EP2815749A1 (fr) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Forme solide de 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione ayant un réseau de diffraction de rayons X spécifique |
| JP6933465B2 (ja) * | 2013-12-31 | 2021-09-08 | アセンディア ファーマシューティカルズ，エルエルシー | 難水溶性化合物のための医薬組成物 |
| WO2015121649A1 (fr) * | 2014-02-12 | 2015-08-20 | Cipla Limited | Composition pharmaceutique contenant du vémurafénib |
| UY36046A (es) * | 2014-03-26 | 2015-10-30 | Millennium Pharm Inc | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso |
| CZ2015250A3 (cs) | 2015-04-14 | 2016-10-26 | Zentiva, K.S. | Amorfní formy vemurafenibu |
| CN105126111A (zh) * | 2015-09-30 | 2015-12-09 | 清华大学 | 提高索拉非尼生物利用度的制剂 |
| CA3049926A1 (fr) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Inhibiteurs de proteine kinase pour favoriser la regeneration du foie, ou pour reduire ou prevenir la mort des hepatocytes |
| SI3644970T1 (sl) * | 2017-06-30 | 2022-05-31 | Acrotech Biopharma Llc | Nove oralne formulacije belinostata |
| TWI833710B (zh) * | 2017-10-06 | 2024-03-01 | 香港商慧源香港創新有限公司 | 高單位含量口服型紫杉烷組合物及方法 |
| JPWO2021006267A1 (fr) * | 2019-07-08 | 2021-01-14 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19539363A1 (de) * | 1995-10-23 | 1997-04-24 | Basf Ag | Verfahren zur Herstellung von festen Arzneiformen |
| US6375986B1 (en) * | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
| CN101091695B (zh) * | 2003-02-03 | 2011-01-19 | 诺瓦提斯公司 | 药物制剂 |
| EP1832281A1 (fr) * | 2006-03-10 | 2007-09-12 | Abbott GmbH & Co. KG | Procédé pour la production d'une dispersion solide d'un ingredient actif |
| EP1880715A1 (fr) * | 2006-07-19 | 2008-01-23 | Abbott GmbH & Co. KG | Composition de solubilisation acceptable sur le plan pharmaceutique et forme posologique contenant celle-ci |
| JP2011513301A (ja) † | 2008-02-28 | 2011-04-28 | バイアル−ポルテラ アンド シーエー，エス．エー． | 難溶性薬剤のための医薬組成物 |
| EP2406259A1 (fr) * | 2009-03-11 | 2012-01-18 | Plexxikon, Inc. | Dérivés de pyrrolo [2, 3-b]pyridine pour l'inhibition des kinases raf |
| AU2010232670B2 (en) * | 2009-04-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof |
| HUE062892T2 (hu) * | 2010-03-25 | 2023-12-28 | Vertex Pharma | (R)-1(2,2-difluorbenzo[d][1,3]dioxol-5-il)-N-(1-(2,3-dihidroxipropil)-6-fluor-2-(1-hidroxi- 2-metilpropán-2-il)-1H-indol-5-il)ciklopropánkarboxamid elõállítása és köztitermékei |
-
2012
- 2012-12-06 US US13/706,390 patent/US20130172375A1/en not_active Abandoned
- 2012-12-10 EP EP12801538.5A patent/EP2790699B2/fr active Active
- 2012-12-10 HU HUE12801538A patent/HUE034548T2/en unknown
- 2012-12-10 WO PCT/EP2012/074884 patent/WO2013087546A1/fr active Application Filing
- 2012-12-10 PL PL12801538T patent/PL2790699T5/pl unknown
- 2012-12-10 RU RU2014127142A patent/RU2014127142A/ru not_active Application Discontinuation
- 2012-12-10 MX MX2014006693A patent/MX348654B/es active IP Right Grant
- 2012-12-10 KR KR1020147016267A patent/KR101637793B1/ko active IP Right Grant
- 2012-12-10 DK DK12801538.5T patent/DK2790699T3/en active
- 2012-12-10 BR BR112014010290A patent/BR112014010290B8/pt active IP Right Grant
- 2012-12-10 JP JP2014546435A patent/JP5936705B2/ja active Active
- 2012-12-10 CA CA2850706A patent/CA2850706C/fr active Active
- 2012-12-10 CN CN201280061576.8A patent/CN103998037B/zh active Active
- 2012-12-10 ES ES12801538T patent/ES2627531T5/es active Active
- 2012-12-10 SI SI201230958A patent/SI2790699T1/sl unknown
-
2018
- 2018-01-16 US US15/872,822 patent/US20180369388A1/en not_active Abandoned
-
2019
- 2019-11-25 US US16/694,713 patent/US20200330600A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014127142A (ru) | 2016-02-10 |
| BR112014010290B1 (pt) | 2022-11-01 |
| MX2014006693A (es) | 2014-07-14 |
| US20200330600A1 (en) | 2020-10-22 |
| US20180369388A1 (en) | 2018-12-27 |
| MX348654B (es) | 2017-06-21 |
| CA2850706A1 (fr) | 2013-06-20 |
| HUE034548T2 (en) | 2018-02-28 |
| US20130172375A1 (en) | 2013-07-04 |
| PL2790699T5 (pl) | 2020-06-29 |
| KR20140096124A (ko) | 2014-08-04 |
| PL2790699T3 (pl) | 2017-08-31 |
| KR101637793B1 (ko) | 2016-07-07 |
| DK2790699T3 (en) | 2017-06-19 |
| JP2015500306A (ja) | 2015-01-05 |
| JP5936705B2 (ja) | 2016-06-22 |
| EP2790699A1 (fr) | 2014-10-22 |
| WO2013087546A1 (fr) | 2013-06-20 |
| BR112014010290A2 (pt) | 2017-05-02 |
| CN103998037B (zh) | 2018-02-16 |
| BR112014010290B8 (pt) | 2022-11-29 |
| EP2790699B2 (fr) | 2020-01-01 |
| CA2850706C (fr) | 2020-05-12 |
| ES2627531T3 (es) | 2017-07-28 |
| ES2627531T5 (es) | 2020-07-23 |
| EP2790699B1 (fr) | 2017-04-05 |
| CN103998037A (zh) | 2014-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2790699T3 (pl) | Kompozycja farmaceutyczna wysokotopliwego związku hydrofobowego o polepszonej dostępności biologicznej | |
| HK1203514A1 (en) | -amino acid compounds for liver isease | |
| AP3864A (en) | Pharmaceutical composition | |
| PL2776416T3 (pl) | Związki farmaceutyczne | |
| IL230861A (en) | A rapidly dissolving pharmaceutical composition | |
| AP3656A (en) | Pharmaceutical compositions | |
| GB201118232D0 (en) | Pharmaceutical composition | |
| HK1182638A1 (en) | Solid pharmaceutical composition containing benzimidazole derivative | |
| EP2702989A4 (fr) | Composition pharmaceutique stable | |
| ZA201307593B (en) | Antihypertensive pharmaceutical composition | |
| HK1201534A1 (en) | Pharmaceutical compounds | |
| HK1189158A1 (en) | Pharmaceutical composition | |
| GB201119799D0 (en) | Pharmaceutical compounds | |
| GB201118876D0 (en) | Pharmaceutical compounds | |
| GB201113163D0 (en) | Pharmaceutical compounds | |
| EP2727593A4 (fr) | Composition pharmaceutique contenant du nicorandil | |
| EP2711010A4 (fr) | Composition pharmaceutique | |
| HUP1100444A2 (en) | Pharmaceutical composition | |
| ZA201308414B (en) | Solid pharmaceutical composition | |
| EP2727594A4 (fr) | Nouvelle composition pharmaceutique | |
| HUP1100445A2 (en) | Pharmaceutical composition | |
| EP2714715A4 (fr) | Compositions pharmaceutiques | |
| GB201118875D0 (en) | Pharmaceutical compounds | |
| GB201118874D0 (en) | Pharmaceutical compounds | |
| GB201117359D0 (en) | Pharmaceutical compounds |